You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting
|
|---|---|
| Published in |
Pediatric Rheumatology, July 2018
|
| DOI | 10.1186/s12969-018-0255-8 |
| Pubmed ID | |
| Authors |
Giovanna Ferrara, Greta Mastrangelo, Patrizia Barone, Francesco La Torre, Silvana Martino, Giovanni Pappagallo, Angelo Ravelli, Andrea Taddio, Francesco Zulian, Rolando Cimaz, On behalf of the Rheumatology Italian Study Group |
| Abstract |
Conventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which methotrexate (MTX) is the most commonly prescribed. However, there is a lack of consensus-based clinical and therapeutic recommendations for the use of MTX in the management of patients with JIA. Therefore, the Methotrexate Advice and RecommendAtions on Juvenile Idiopathic Arthritis (MARAJIA) Expert Meeting was convened to develop evidence-based recommendations for the use of MTX in the treatment of JIA. The preliminary executive committee identified a total of 9 key clinical issues according to the population, intervention, comparator, outcome (PICO) approach, and performed an evidence-based, systematic, literature review. During the subsequent Expert Meeting, the relevant evidence was assessed and graded, and 10 recommendations were made. Recommendations relating to the efficacy, optimal dosing and route of administration and duration of treatment with MTX in JIA, and to the issue of folic acid supplementation to prevent MTX side effects, use of MTX in the treatment of chronic JIA-associated uveitis, combination treatment with biologic agents, and the use of vaccinations in patients with JIA were developed. The selected topics were considered to represent clinically important issues facing clinicians caring for patients with JIA. Evidence was insufficient to formulate recommendations for the use of biomarkers predictive of treatment response. These consensus recommendations provide balanced and evidence-based recommendations designed to have broad value for physicians and healthcare clinicians involved in the clinical management of patients with JIA. |
X Demographics
The data shown below were collected from the profiles of 26 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 7 | 27% |
| Colombia | 2 | 8% |
| Mexico | 2 | 8% |
| Venezuela, Bolivarian Republic of | 1 | 4% |
| Singapore | 1 | 4% |
| Peru | 1 | 4% |
| United Kingdom | 1 | 4% |
| Germany | 1 | 4% |
| El Salvador | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 85% |
| Practitioners (doctors, other healthcare professionals) | 2 | 8% |
| Scientists | 1 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 135 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 16 | 12% |
| Student > Ph. D. Student | 16 | 12% |
| Researcher | 13 | 10% |
| Student > Master | 12 | 9% |
| Student > Bachelor | 12 | 9% |
| Other | 21 | 16% |
| Unknown | 45 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Nursing and Health Professions | 6 | 4% |
| Immunology and Microbiology | 5 | 4% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Other | 10 | 7% |
| Unknown | 49 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2022.
All research outputs
#791,191
of 23,001,641 outputs
Outputs from Pediatric Rheumatology
#7
of 703 outputs
Outputs of similar age
#18,842
of 326,561 outputs
Outputs of similar age from Pediatric Rheumatology
#2
of 12 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 703 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,561 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.